Patients with triple negative breast cancer (ER−/PR−/HER2−) express CD44+CD49f+CD133/2 in breast tumor tissues, which positively correlate with a stem-cell-derived tumorigenic signature [23]. This evidence concerns the gene PROM1 and triple-negative breast carcinoma.